<level type="section">
  <num>48-842.02</num>
  <heading>Definitions.</heading>
  <text>For the purposes of this chapter, the term:</text>
  <level>
    <level>
      <num>(1)</num>
      <text>"Medication advisory committee" means any committee or panel that is responsible for making recommendations or decisions regarding a formulary to be used by a health program administered by the government of the District of Columbia.</text>
    </level>
    <level>
      <num>(2)</num>
      <text>"Pharmaceutical company" means any entity that is engaged in, either directly or indirectly, the production, preparation, propagation, compounding, manufacturing, conversion or processing of a drug or biological product, including any person acting as its agent or representative.</text>
    </level>
  </level>
  <level>
    <type>annotations</type>
    <level>
      <heading>CREDIT(S)</heading>
      <text>(Mar. 26, 2008, D.C. Law 17-131, ยง 302, 55 DCR 1659.)</text>
    </level>
    <level>
      <heading>HISTORICAL AND STATUTORY NOTES</heading>
      <level>
        <heading>Legislative History of Laws</heading>
        <text>For Law 17-131, see notes following ยง 48-842.01.</text>
      </level>
    </level>
  </level>
</level>
